Knowledge

Deep vein thrombosis (DVT) medical devices encompass tools for prevention, diagnosis, and treatment, including trocars for access, post-surgical compression hardware for prophylaxis, and vascular devices like IVC filters and thrombectomy systems. Material science, operational safety, and surgical integration are paramount for their clinical success and patient safety. How Do Material Configurations Impact DVT Device Performance? […]

The technological foundation of ICU equipment is defined by precision-engineered materials, rigorous safety protocols, and seamless system integration to ensure reliable, biocompatible, and efficient life support in the most demanding clinical environments. How are raw material configurations for critical components like ventilator valves and patient monitors selected? The selection process prioritizes mechanical integrity, chemical inertness,

Trocars are specialized surgical access devices used in laparoscopic and minimally invasive procedures to create a sealed pathway through the abdominal wall, allowing for the insertion of instruments like cameras and graspers while maintaining pneumoperitoneum. Their design is critical for preventing complications such as port-site herniation and ensuring procedural efficiency. What are the primary raw

Testicle rods, or scrotal support rods, are urological prosthetics crafted from medical-grade silicone to restore anatomical structure and patient comfort post-orchiectomy. Their design hinges on precise raw material configurations, stringent operational safety protocols, and biocompatibility to ensure efficacy and patient safety within surgical settings. What are the key raw material configurations for medical-grade silicone in

The global testicular implants market is being estimated at about $71 million in 2026 in the report you referenced, reflecting steady demand in reconstructive urology and related specialty care. For healthcare procurement teams and marketplace operators, this matters because it affects sourcing, supplier vetting, lifecycle planning, and trade flows for silicone and saline-filled prostheses. HHG

The EAU 2026 testicular cancer guidance reinforces standardized counseling around testicular prosthesis placement after orchidectomy, with stronger emphasis on timing, shared decision-making, and documentation. For healthcare procurement teams, that matters because prosthesis availability, sterile handling, supplier vetting, and post-surgical supply coordination now sit closer to the center of care pathways. In a B2B medical equipment

NHS Supply Chain’s “Surgical Implants for Men’s and Women’s Health” framework is a 24-month procurement route that starts on 1 April 2026 and runs to 31 March 2028, with an option to extend for another 24 months. It gives NHS trusts and eligible UK healthcare buyers a structured way to source vetted suppliers, either through

Tariffs and supply‑chain disruptions are increasing baseline manufacturing and import costs for cooling components, electronic sensors, and assemblies used in professional body‑sculpting and other aesthetic devices. As a result, certified refurbished medical equipment offers clinics, hospitals, and dealers a more cost‑effective, compliant alternative to brand‑new technology, while still meeting clinical and regulatory expectations. This shift

CoolSculpting Elite is the newer dual-applicator evolution of CoolSculpting, while the original Legacy platform remains a widely understood cryolipolysis system for clinics buying used or pre-owned equipment. For B2B buyers, the real question is not clinical hype but operational fit: throughput, refurbishment status, serviceability, documentation, and resale value. In a marketplace like HHG GROUP, both

Cryolipolysis demand is rising in 2026 because clinics want non-invasive body contouring equipment that can generate revenue without major downtime, while buyers increasingly prefer used medical equipment, refurbished devices, and platform-mediated transactions that reduce acquisition risk. The market report projects the global cryolipolysis market at $1.89 billion in 2026, up from $1.67 billion in 2025,